ESC 365 - Practical recommendations for the management of patients with CV disease by using hsTnI.

ESC Premium Access

Practical recommendations for the management of patients with CV disease by using hsTnI.

Session: Cardiovascular risk assessment and prevention: Where do we stand now?

Topic: Risk Factors and Prevention

Speaker: Professor T. Omland (Nordbyhagen, NO)

Sponsored by Abbott

Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

About the speaker

Professor Torbjorn Omland

Akershus University Hospital, Nordbyhagen (Norway)

6 presentations

1 follower

4 more presentations in this session

Welcome and Introduction.

Speaker: Professor C. Lam (Singapore, SG)

The role of troponins in primary prevention of CV events: Case report.

Speaker: Professor N. Sattar (Glasgow, GB)

The confirmed role of LDL-cholesterol for the prevention and management of cardiovascular disease in patients with diabetes.

Speaker: Professor G. Rudofsky (Olten, CH)

Live Q and A session.

Access the full session

Cardiovascular risk assessment and prevention: Where do we stand now?

Speakers: Professor T. Omland, Professor C. Lam, Professor N. Sattar, Professor G. Rudofsky

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

Related content

EHRA Premium Access

Effectiveness and safety of edoxaban in 27,333 patients from ETNA-AF with and without a history of intracranial haemorrhage after 2 years of treatment

4 April 2022

ESC Premium Access

An asymptomatic patient with positive treadmill test during screening for life insurance and significant proximal LAD disease in coronary CT angiography: how to implement the guidelines and take-home message.

27 August 2021

ESC Premium Access

Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage

27 August 2021

ESC 365 is supported by